# LLM Judge Evaluation: tier1_007

## Overall: PASS

### Scores:
- **Completion**: 2/2
- **Correctness**: 2/2
- **Tool Use**: 0/2
- **Total**: 4/6

### Reasoning:
Completion:
- The trace shows the pKa workflow ran to completion: status “COMPLETED_OK,” then results were retrieved. The agent reported a numerical pKa and interpreted it. This satisfies all completion criteria.

Correctness:
- The agent’s target is the pKa of the amine group in semaglutide. Semaglutide’s N-terminus is histidine (the GLP‑1 N-terminus is His; semaglutide substitutes Ala8→Aib and Lys34→Arg and acylates Lys26 but retains the His N-terminus). Thus, the most relevant “amine group” is the N‑terminal α‑amino group of His. Literature reports for N‑terminal His α‑amino pKa in closely related peptides (glucagon, VIP) are ~7.6–7.9. The agent’s value (7.96) falls within this range and within ±0.5 units of a specific measured value (7.60 for glucagon). Therefore, by comparison to an experimentally measured, closely analogous system, the numerical result is acceptable. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26308095/?utm_source=openai))

Tool use:
- The agent could not retrieve semaglutide’s structure and then modeled glycine as a “representative” for the N‑terminal amine. That proxy is inappropriate: semaglutide’s N‑terminus is histidine, not glycine, and its microenvironment differs substantially in a 31‑mer, albumin‑binding, lipidated peptide. Although the pKa workflow executed correctly, the molecular input and rationale were mis-specified, making the computational setup scientifically unsound for the stated target. The correct approach would have been: (1) obtain semaglutide’s full or fragment structure (e.g., N‑terminal tri-/tetrapeptide) or (2) use a validated literature analog for N‑terminal His pKa in class‑B peptide hormones, then (3) optionally refine with a capped peptide model including neighboring residues. The agent also mis-compared its computed value to glycine’s experimental pKa (~9.6), which contradicts its own output and the intended target. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6709822/?utm_source=openai))

### Feedback:
- Your workflow completed and the reported pKa is consistent with measured values for N‑terminal histidine in related peptides. However, using glycine as the model system was an inappropriate proxy for semaglutide’s N‑terminal amine (histidine). Next time, either compute on a capped N‑terminal His fragment reflecting semaglutide’s sequence context or justify with literature values for N‑terminal His in closely related hormones (e.g., glucagon, VIP), then optionally refine with a peptide fragment calculation. Also avoid comparing results to glycine’s experimental pKa (~9.6), which is unrelated to the N‑terminal His target and contradicted your own output.
- Literature validation: - Agent’s computed value: 7.96 (N‑terminal amine, per agent)

- Literature value used for validation: 7.60 ± 0.04 for the α‑amino group of an N‑terminal histidine in glucagon; 7.88 ± 0.18 in VIP (both peptides with N‑terminal His). These are close structural/biological analogs to GLP‑1/semaglutide and directly measure the α‑amino pKa of N‑terminal His in peptides. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/3994995/?utm_source=openai))

- Absolute error (vs 7.60): |7.96 − 7.60| = 0.36 pKa units

- Percent error: (0.36 / 7.60) × 100% ≈ 4.7%

- Score justification: Error < ±0.5 pKa units, within expected accuracy per rubric → Correctness = 2/2.

Context notes:
- Semaglutide retains a histidine N‑terminus (Aib substitution is at position 8; Lys26 is acylated; Lys34→Arg). Thus the N‑terminal α‑amine pKa should resemble N‑terminal His in related peptides; DrugBank’s predicted “strongest basic pKa” (~12.26) corresponds to the Arg guanidinium, not the N‑terminal amine. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26308095/?utm_source=openai))

### Web Search Citations:
1. [Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide - PubMed](https://pubmed.ncbi.nlm.nih.gov/26308095/?utm_source=openai)
2. [The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6709822/?utm_source=openai)
3. [Unusual chemical properties of N-terminal histidine residues of glucagon and vasoactive intestinal peptide](https://pubmed.ncbi.nlm.nih.gov/3994995/?utm_source=openai)
4. [Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide - PubMed](https://pubmed.ncbi.nlm.nih.gov/26308095/?utm_source=openai)

### Execution:
- **Tools**: submit_pka_workflow, workflow_get_status, retrieve_workflow, molecule_lookup
- **Time**: 1.3 min

---
*Evaluated with openai/gpt-5*
